A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Latest Information Update: 08 Nov 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms PRISM
- 06 Nov 2023 Results evaluating whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile, published in the Journal of Clinical Oncology
- 14 Dec 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.